121 Erma Byrd Building
PO Box 9530
- Curriculum Vitae
- Download CV
Synthesis and Biological Evaluation of Pentacycloundecylamines and Triquinylamines as Voltage-Gated Calcium Channel Blockers.
Young LM, Geldenhuys WJ, Domingo OC, Malan SF, Van der Schyf CJ.
Arch Pharm (Weinheim). 2016 Feb 19. doi: 10.1002/ardp.201500293. [Epub ahead of print] PMID: 26892182
Evolution of a Natural Products and Nutraceuticals Course in the Pharmacy Curriculum.
Geldenhuys WJ, Cudnik ML, Krinsky DL, Darvesh AS.
Am J Pharm Educ. 2015 Aug 25;79(6):82. doi: 10.5688/ajpe79682. PMID: 26430269
A novel biomechanical analysis of gait changes in the MPTP mouse model of Parkinson's disease.
Geldenhuys WJ, Guseman TL, Pienaar IS, Dluzen DE, Young JW.
PeerJ. 2015 Aug 11;3:e1175. doi: 10.7717/peerj.1175. eCollection 2015. PMID: 26339553
Molecular determinants of blood-brain barrier permeation.
Geldenhuys WJ, Mohammad AS, Adkins CE, Lockman PR.
Ther Deliv. 2015;6(8):961-71. doi: 10.4155/tde.15.32. Epub 2015 Aug 25. PMID: 26305616
CArG-driven GADD45α activated by resveratrol inhibits lung cancer cells.
Shi Q, Geldenhuys W, Sutariya V, Bishayee A, Patel I, Bhatia D.
Genes Cancer. 2015 May;6(5-6):220-30. PMID: 26124921
Novel thiazolidinedione mitoNEET ligand-1 acutely improves cardiac stem cell survival under oxidative stress.
Logan SJ, Yin L, Geldenhuys WJ, Enrick MK, Stevanov KM, Carroll RT, Ohanyan VA, Kolz CL, Chilian WM.
Basic Res Cardiol. 2015 Mar;110(2):19. doi: 10.1007/s00395-015-0471-z. Epub 2015 Mar 1. PMID: 25725808
Generation and characterization of ATP analog-specific protein kinase Cδ.
Kumar V, Weng YC, Geldenhuys WJ, Wang D, Han X, Messing RO, Chou WH.
J Biol Chem. 2015 Jan 23;290(4):1936-51. doi: 10.1074/jbc.M114.598698. Epub 2014 Dec 10. PMID: 25505183
Pharmacotherapy of Alzheimer's disease: current and future trends.
Geldenhuys WJ, Darvesh AS.
Expert Rev Neurother. 2015 Jan;15(1):3-5. doi: 10.1586/14737175.2015.990884. Epub 2014 Dec 8. Review. PMID: 25481975
Screening and identification of novel compounds with potential anti-proliferative effects on gallium-resistant lung cancer through an AXL kinase pathway.
Oyewumi MO, Alazizi A, Liva S, Lin L, Geldenhuys WJ.
Bioorg Med Chem Lett. 2014 Sep 15;24(18):4553-6. doi: 10.1016/j.bmcl.2014.07.072. Epub 2014 Aug 2. PMID: 25131538
Methyl Yellow: A Potential Drug Scaffold for Parkinson's Disease.
Geldenhuys WJ, Kochi A, Lin L, Sutariya V, Dluzen DE, Van der Schyf CJ, Lim MH.
Chembiochem. 2014 Jul 8. doi: 10.1002/cbic.201300770. [Epub ahead of print] PMID: 25045125
About Werner Geldenhuys
Dr. Geldenhuys graduated from Potchefstroom University, South Africa (now North-West University) in 1999 with a bachelor of Pharmacy degree. He then went on the receive a Doctor of Philosophy in medicinal chemistry/neuroscience (2004) after completing a Master’s degree in medicinal chemistry (2002), both from North-West University. After graduation he did a post-doctoral research at Texas Tech School of Pharmacy. In 2007 he joined as the first faculty member in the Department of Pharmaceutical Sciences of the newly established College of Pharmacy at Northeast Ohio Medical University (NEOMED), Rootstown, OH. His research is focused on the development of novel neuroprotective compounds to slow the progression of neurodegenerative diseases including Parkinson’s and Alzheimer’s disease and stroke.